Market Overview

Celgene Says ABRAXANE Demonstrates Statistically Significant Improvement

Related CELG
Celgene Shares Higher On Positive Crohn's Patient Data
Watch These 5 Huge Call Purchases In Monday Trade
Notable earnings before Thursday's open (Seeking Alpha)

Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that its phase III study of ABRAXANE^® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival. In the study, ABRAXANE in combination with gemcitabine demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone.

Posted-In: News FDA


Related Articles (CELG)

View Comments and Join the Discussion!